Evidence map›Paper›PMID 42278599›Full record

ReviewInternational journal of molecular sciences2026

Toll-like Receptor 3 as a Context-Dependent Molecular Switch in Epithelial Cancers: Balancing Cell Death and Tumor-Supportive Programs.

Amarilis Pérez-Baños, Andrés Tittarelli

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amarilis Pérez-BañosInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.ORCID 0009-0005-6674-6678
Andrés TittarelliInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.ORCID 0000-0003-4129-9734

Funding

National Agency for Research and Development 1251793
6 · The paper itself

Abstract

Toll-like receptor 3 (TLR3) is a double-stranded RNA sensor that plays a dual and context-dependent role in epithelial cancers, promoting either regulated cell death (RCD) or tumor-supportive programs. While TLR3 activation has been widely explored for its capacity to induce apoptosis or necroptosis and enhance antitumor immunity, accumulating evidence indicates that cancer cells can use TLR3 signaling to sustain proliferation, migration, stemness, and therapy resistance. In this review, we provide a comprehensive and mechanistic analysis of TLR3 signaling in epithelial cancers, encompassing canonical and non-canonical modules that regulate cancer cell fate. We examine how TLR3 activation engages interconnected RCD programs, including apoptosis, necroptosis, and immunogenic cell death, and contrast these with pathways driving tumor plasticity and progression. Importantly, we discuss the key determinants governing TLR3 signaling output, including signaling complex composition; ligand origin and delivery; TLR3 subcellular localization; and cancer cell-intrinsic factors such as genetic, epigenetic, and metabolic states. We propose an integrative framework in which TLR3 signaling influences cancer cell fate according to cellular and microenvironmental context.

Indexed as

Neoplasms, Glandular and EpithelialToll-Like Receptor 3AnimalsApoptosisCell DeathHumansInnate Immunity RecognitionSignal TransductionTumor MicroenvironmentTLR3 protein, humanToll-Like Receptor 3cancerregulated cell deathsignaling pathwaystoll-like receptor 3tumor cell plasticity

Identifiers

PMID42278599
PMCPMC13256595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.